Royal London Asset Management’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-275,801
Closed -$27.4M 667
2019
Q3
$27.4M Sell
275,801
-5,323
-2% -$506K 0.21% 115
2019
Q2
$26M Sell
281,124
-4,196
-1% -$398K 0.25% 101
2019
Q1
$26.9M Sell
285,320
-322,089
-53% -$28.2M 0.21% 113
2018
Q4
$37.9M Buy
607,409
+216,797
+56% +$16M 0.33% 72
2018
Q3
$35M Buy
390,612
+79,817
+26% +$7.05M 0.36% 64
2018
Q2
$24.7M Buy
+310,795
New +$25.8M 0.25% 95
2016
Q2
$26M Sell
263,112
-19,077,339
-99% -$1.97B 0.42% 54
2016
Q1
$193K Buy
19,340,451
+19,056,738
+6,717% +$1.96B 0.28% 84
2015
Q4
$34.2M Buy
283,713
+3,722
+1% +$431K 0.53% 42
2015
Q3
$30.3M Buy
+279,991
New +$34.7M 0.49% 50
2014
Q4
$289K Buy
254,644
+57,615
+29% +$6.08M 0.55% 44
2014
Q3
$18.8M Buy
197,029
+7,931
+4% +$716K 0.47% 47
2014
Q2
$16.3M Sell
189,098
-872
-0.5% -$66.3K 0.37% 63
2014
Q1
$14.3M Sell
189,970
-8,012
-4% -$634K 0.33% 75
2013
Q4
$16.8M Buy
197,982
+1,372
+0.7% +$109K 0.43% 56
2013
Q3
$15.5M Buy
196,610
+2,292
+1% +$161K 0.42% 56
2013
Q2
$11.5M Buy
+194,318
New +$11.7M 0.34% 66

Other funds holding CELG

Royal London Asset Management's CELG Position: Q4 2019 in Review

Royal London Asset Management sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 275,801 shares — an estimated $27.4M sold.

Royal London Asset Management first reported a position in CELG in Q2 2013 and held it in 17 quarters. The position peaked at $37.9M in Q4 2018. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Royal London Asset Management reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Royal London Asset Management sold 275,801 Celgene Corp shares in Q4 2019, an estimated $27.4M.
  • Royal London Asset Management first reported a position in Celgene Corp in Q2 2013 and held it in 17 quarters.
  • Royal London Asset Management's Celgene Corp position peaked at $37.9M in Q4 2018.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Royal London Asset Management's 13F filing for Q4 2019, filed 5 Feb 2020.